Wird geladen...
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185(her2/neu) and the EGFR–p185(her2/neu) complexes
2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2008
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2819401/ https://ncbi.nlm.nih.gov/pubmed/18264138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2008.13 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|